Target Protein Equipment Supplied In California

Moving beyond more traditional approaches that are used to evoke adaptive immunity or that directly target pathogens, where the development of resistance can occur, we plan to target host proteins as a means of creating host-directed therapies with high barriers to resistance. We believe that by leveraging the power of innate immunity, we can ...

Antibody discovery is challenging. Only 5 of every 5000 concepts make it into the clinic.1 Many antibody failures can be attributed to a lack of specificity for disease-causing cells versus healthy cells and a lack of efficacy – both potentially due to binding the wrong epitope. ...

Glial Fibrillary Acidic Protein (GFAP) immunostaining (RED) of mixed cortical mouse brain cultures from Gerry Shaw's EnCorBio (Aves Labs, 1:500 dilution). Secondary antibody (Texas Red goat anti-chicken IgY) is from Jackson ImmunoResearch). The BLUE is DAPI staining of nuclei of all cells, including non-GFAP-positive cells. ...

Staining of a tissue section through the midbrain region of an adult mouse for GFP (green) and Tryptophan Hydroxylase-positive neurons (RED). ...

Human Glial Fibrillary Acidic Protein (GFAP) is a 49,749 dalton protein (432 amino acids) expressed by astrocytes of the central nervous system. GFAP is an intermediate filament protein and acts as an intra-cellular structural component of the astrocytic cytoskeleton. ...

Antibodies are one of the most important everyday reagents for biomedical science. In recent years, a number of studies have questioned the reliability of published data and highlighted how low-quality antibodies have contributed to a lack of consistent results (Bordeaux et al. 2010; Prinz et al. 2011; Baker and Dolgin 2017). We believe antibodies need to be properly validated before they can be ...

We work with both small startups and big pharmas to leverage digital power in order to enable the development of new therapies. We contribute to the entire drug discovery process, from target identification and validation, to compound design and clinical trials. We make bioinformatic workflows and software with human-readable code, as well as machine learning models that ...